Richard Peters, Md, Phd

At Aura Biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. By safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. Our lead program in ocular melanoma (OM), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. The goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. By enabling physicians to treat cancer more selectively, effectively and safely than they can do today, we aim to eliminate the need for invasive procedures that carry significant morbidity, including vision loss and often do little to improve a patient’s overall survival.

TellBio, Inc is a development stage biotechnology company based in Beverly, Massachusetts, with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutic platform, TellDx and TellRx, respectively. The foundation of the Company’s approach – detection of and targeting CTCs – is exclusively licensed from Massachusetts General Hospital and is based on decades of academic and clinical research. TellBio’s vision is to free patients and their families from the tyranny of cancer via both its TellDx and TellRx platforms. TellDx is a fully functional diagnostic solution aimed at detecting live CTCs from patient liquid biopsies. TellRx is the therapeutics platform that generates novel anti-cancer medicines by specifically targeting CTCs. The synergy of these platforms offers TellBio a unique opportunity to detect CTCs via a first-in-class, best-in-class microfluidic diagnostic platform and target CTCs with novel therapeutics to improve outcomes of patients with cancer.

At Aura Biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. By safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. Our lead program in ocular melanoma (OM), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. The goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. By enabling physicians to treat cancer more selectively, effectively and safely than they can do today, we aim to eliminate the need for invasive procedures that carry significant morbidity, including vision loss and often do little to improve a patient’s overall survival.

We are a commercial-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system and few to no treatment options. We have successfully developed mavorixafor, receiving FDA approval for XOLREMDI® (mavorixafor) in its first indication, and are currently executing our US launch. We are also advancing mavorixafor for additional rare disease patient populations, and expect to initiate a pivotal, global Phase 3 clinical trial in people with certain chronic neutropenic disorders. With a focus on CXCR4 and immune system biology, we continue to leverage our expertise both at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria to further advance our patient-centric mission.